In this episode of Denatured, you'll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into the long-overlooked hair loss space, exploring why true innovation has lagged, how a regenerative approach aims to reactivate dormant follicles and what early proof-of-concept means for patients.Host<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/jennifersmithparker/" target="_blank">Jennifer C. Smith-Parker</a>, Director of Insights, BioSpaceGuests<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/daniel-gil-165067aa/" target="_blank">Daniel Gil</a>, CEO, Pelage Pharmaceuticals<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/francisco-ramirez-valle/" target="_blank">Francisco Ramírez-Valle</a>, Senior Vice President, Immunology Discovery, Eli LillyDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.